Fang L, Turtschi S, Mozaffarieh Maneli
Department of Ophthalmology, University of Basel, Mittlere Strasse 91, 4031, Basel, Switzerland.
Graefes Arch Clin Exp Ophthalmol. 2015 Jun;253(6):935-9. doi: 10.1007/s00417-015-3001-7. Epub 2015 Apr 12.
The purpose was to measure the retinal venous pressure (RVP) in both eyes of primary open-angle glaucoma (POAG) patients before and 3 weeks after treatment with low-dosed Nifedipine.
This retrospective study included 20 POAG patients who were treated with Nifedipine (5 mg daily) and 20 untreated control POAG patients. In both the treated and untreated control group, a distinction was made between those patients who had the Flammer-Syndrome (FS) and those who did not. The RVP was measured in all patients bilaterally at baseline and 3 weeks later by means of contact lens ophthalmodynamometry and the RVP measurements of the treated POAG patients were compared to the RVPs of the untreated POAG controls. Ophthalmodynamometry is done by applying an increasing force on the eye via a contact lens. The minimum force required to induce a venous pulsation is called the ophthalmodynamometric force (ODF). The RVP is defined and calculated as the sum of ODF and intraocular pressure (IOP) [RVP = ODF + IOP].
The RVP decreased significantly after 3 weeks in both eyes of patients treated with low-dosed Nifedipine compared to the untreated group (mean decrease of 12.5 mmHg (SD 12.5), P < 0.001). A larger response to therapy was found in patients with the FS compared to patients lacking the FS (mean decrease of 16.07 vs. 7.28 mmHg, confidence Interval (CI): 5.2 to 9.3 vs. 12.3 to 19.7; P < 0.001). No significant differences were accounted for in the IOP's of the patients after treatment. In the untreated control group, no significant differences were accounted for either in the RVP or the IOP after 3 weeks.
Treatment with low-dosed Nifedipine decreases RVP in both eyes of glaucoma patients, particularly in those with the Flammer-Syndrome. This effect may be due to the partial inhibition of Endothelin-1 (ET-1) by Nifedipine.
本研究旨在测量原发性开角型青光眼(POAG)患者双眼在低剂量硝苯地平治疗前及治疗3周后的视网膜静脉压(RVP)。
本回顾性研究纳入了20例接受硝苯地平治疗(每日5mg)的POAG患者和20例未接受治疗的对照POAG患者。在治疗组和未治疗对照组中,均区分了患有弗拉默综合征(FS)的患者和未患该综合征的患者。所有患者在基线时及3周后均通过接触镜式眼压计双侧测量RVP,并将接受治疗的POAG患者的RVP测量值与未治疗的POAG对照患者的RVP进行比较。眼压计测量是通过接触镜对眼睛施加逐渐增加的压力来进行的。诱导静脉搏动所需的最小压力称为眼压计测量力(ODF)。RVP定义并计算为ODF与眼内压(IOP)之和[RVP = ODF + IOP]。
与未治疗组相比,低剂量硝苯地平治疗的患者双眼在3周后RVP显著降低(平均降低12.5mmHg(标准差12.5),P < 0.001)。与未患FS的患者相比,患FS的患者对治疗的反应更大(平均降低分别为16.07mmHg和7.28mmHg,置信区间(CI):5.2至9.3与12.3至19.7;P < 0.001)。治疗后患者的IOP无显著差异。在未治疗的对照组中,3周后RVP和IOP也均无显著差异。
低剂量硝苯地平治疗可降低青光眼患者双眼的RVP,尤其是患有弗拉默综合征的患者。这种作用可能是由于硝苯地平对内皮素-1(ET-1)的部分抑制作用。